BindingDB logo
myBDB logout

78 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28072531 120 Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.EBI Arena Pharmaceuticals
28523115 59 Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DPEBI Novartis Institutes for Biomedical Research
28169162 86 Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.EBI AskAt Inc.
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
28105284 55 Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.EBI Ono Pharmaceutical Co., Ltd.
26985320 89 Discovery of G Protein-Biased EP2 Receptor Agonists.EBI Ono Pharmaceutical Co., Ltd.
27133594 6 Piperidine derivatives as nonprostanoid IP receptor agonists 2.EBI Toray Industries, Inc.
27107947 30 Optimization of amide-based EP3 receptor antagonists.EBI Pfizer Inc.
27020304 31 Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.EBI Lilly Research Laboratories
26996371 27 Piperidine derivatives as nonprostanoid IP receptor agonists.EBI Toray Industries, Inc.
27055938 82 Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.EBI Ono Pharmaceutical Co., Ltd
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26764191 38 Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.EBI Lilly Research Laboratories
26725951 46 Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity.EBI Ono Pharmaceutical Co., Ltd
26091726 41 Discovery and characterization of a potent and selective EP4 receptor antagonist.EBI Lilly Research Laboratories
26061158 136 A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.EBI Amgen Inc.
24279689 56 Prostanoid receptor EP2 as a therapeutic target.EBI Emory University School of Medicine
24021582 52 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.EBI Novartis Institutes for Biomedical Research
 4 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid,2-[3-[2-(furanylmethyl)thio]-1-oxopropyl]hydrazide (SC-51322): A potent PGE2 antagonist and analgesicEBI TBA
24900547 23 Fluorescent Human EP3 Receptor Antagonists.EBI TBA
24900213 25 Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.EBI TBA
19804971 63 Discovery and optimization of CRTH2 and DP dual antagonists.EBI Amgen Inc.
18359630 37 Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.EBI Merck Frosst Canada& Co.
18039575 35 Synthesis and evaluation of a gamma-lactam as a highly selective EP2 and EP4 receptor agonist.EBI EMD-Serono Research Institute, Inc.
18291643 76 Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.EBI Merck Frosst Centre for Therapeutic Research
17931866 47 Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists.EBI EMD-Serono Research Institute
17531488 44 Discovery of novel prostaglandin analogs of PGE2 as potent and selective EP2 and EP4 receptor agonists.EBI EMD Serono Research Institute
16931013 138 Comparison between two classes of selective EP(3) antagonists and their biological activities.EBI Merck Frosst Centre for Therapeutic Research
15664806 104 Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists.EBI Merck Frosst Centre for Therapeutic Research
15914004 34 Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.EBI Fujisawa Pharmaceutical Co., Ltd.
12643927 164 Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.EBI Merck Frosst Centre for Therapeutic Research
21930381 15 Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor.EBI Rottapharm Madaus
21208803 81 The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.EBI Merck Frosst Centre for Therapeutic Research
21036609 38 Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.EBI Merck Frosst Centre for Therapeutic Research
20926294 65 3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.EBI GlaxoSmithKline Pharmaceuticals
20471829 43 Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.EBI Merck Frosst Canada Ltd
20218623 68 Emerging targets in osteoporosis disease modification.EBI Amgen, Inc.
20303752 143 1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists.EBI deCODE Chemistry
19836233 31 Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.EBI deCODE Chemistry, Inc
20163116 116 The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.EBI Merck Frosst Centre for Therapeutic Research
19957930 126 Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent thatEBI deCODE Chemistry, Inc.
19592244 61 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.EBI Novartis Institutes of Biomedical Research
19487124 39 Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.EBI GlaxoSmithKline Pharmaceuticals
19332369 43 Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.EBI GlaxoSmithKline
19307115 89 Discovery of potent and selective DP1 receptor antagonists in the azaindole series.EBI Merck Frosst Centre for Therapeutic Research
19188065 116 3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists.EBI deCODE Chemistry
19121942 57 Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists.EBI deCODE Chemistry, Inc.
17531480 51 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.EBI Novartis Institutes of Biomedical Research
17300164 62 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).EBI Merck Frosst Canada & Co.
16529930 96 Identification of an indole series of prostaglandin D2 receptor antagonists.EBI Merck Frosst Canada & Co.
15935659 17 Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.EBI Fujisawa Pharmaceutical Co., Ltd.
15857112 55 Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.EBI Fujisawa Pharmaceutical Co., Ltd.
15566283 43 Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents.EBI Roche Palo Alto
15026044 90 Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization.EBI Roche Palo Alto
14552786 88 Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.EBI Merck Frosst Centre for Therapeutic Research
12182865 88 Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.EBI Merck Frosst Centre for Therapeutic Research
11708917 33 Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.EBI Procter & Gamble Pharmaceuticals
11454472 107 Design and synthesis of a highly selective EP2-receptor agonist.EBI Minase Research Institute
11266183 32 Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.EBI Merck Frosst Canada & Co.
10715159 112 Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.EBI Procter and Gamble Pharmaceuticals
10509919 103 New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.EBI Merck Frosst Centre for Therapeutic Research
20429779 11 Carbocyclic potential DNA minor groove binders and their biological evaluation.BDB Medical University
26642829 34 Synthesis of 4-[2-(3,4-dimethoxybenzyl)cyclopentyl]-1,2-dimethoxybenzene Derivatives and Evaluations of Their Carbonic Anhydrase Isoenzymes Inhibitory Effects.BDB Atat£rk University
15801831 94 Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.BDB Pfizer
 40 Ring Size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol.BDB Sphinx Laboratories
8809165 120 Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.BDB Upjohn
7658450 20 Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.BDB Upjohn